Aktie A2QK1R JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Jacobio Pharmaceuticals Group Co., Ltd.

Aktien

A2QK1R

KYG4987A1094

1167

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:08:06 30.04.2024 		% 5 Tage % 1. Jan.
1.69 HKD -2.31% Intraday Chart für Jacobio Pharmaceuticals Group Co., Ltd. +15.75% -53.31%
25.04. Jacobio Pharmaceuticals plant Wechsel des Wirtschaftsprüfers MT
09.04. Jacobio präsentiert klinische Daten von Anti-Tumor-Medikamenten auf US-Kongress MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Jacobio Pharmaceuticals Plans Auditor Change
Jacobio to Share Clinical Data of Anti-Tumor Drugs at US Convention
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting
Jacobio Pharmaceuticals Narrows 2023 Loss on Lower R&D Expenses
Jacobio Pharmaceuticals Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Jacobio Pharmaceuticals Gets US FDA Clearance for Phase 1/2 Clinical Trial for Anti-Tumor Drug; Shares Surge 16%
Jacobio Pharmaceuticals Group Co., Ltd. Receives US FDA Investigational New Drug Clearance for P53 Y220C Activator JAB-30300
Hong Kong Stocks Fall as Chinese Central Bank Leaves Key Policy Rate on Hold; Jacobio Falls 11% Despite Drug Progress
China Approves Jacobio's Phase 3 Trial of Non-Small Cell Lung Cancer Drug; Shares Plummet 13%
Jacobio Pharma Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor
Jacobio Presents Clinical Data on Pancreatic Cancer Treatment at Oncology Meet; Shares Fall 7%
Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors At the 2024 ASCO GI
Jacobio to Present Clinical Results of Pancreatic Cancer Drug in US Meet; Shares Jump 3%
Jacobio Pharmaceuticals Group Co., Ltd. Announces Clinical Results in the Oral Abstract Session of Clinical Oncology Gastrointestinal Cancers Symposium
Jacobio Presents Clinical Data on Anti-Tumor Drug at Oncology Congress
Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with Jab-3312 At Esmo
Jacobio Pharmaceuticals Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
China Grants Breakthrough Therapy Status to Jacobio's Pancreatic Cancer Treatment; Shares Rise 5%
Jacobio Pharmaceuticals Group Co., Ltd.'S In-House KRAS G12C Inhibitor Jab-21822 Granted Breakthrough Therapy Designation for Pancreatic Cancer Patients
Jacobio Earmarks HK$100 Million for Share Buyback
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QK1R Aktie
  4. Nachrichten Jacobio Pharmaceuticals Group Co., Ltd.
  5. Andere Sprachen